Naveen Padmanabhan1, Barath Raj Kumar1, Ansar Pullampara Pookunju2, Ayyapan Srinivasan3, Vikash Mahajan4. 1. Registrar, Department of Surgical Oncology, Apollo Speciality Hospitals , Chennai, India . 2. Senior Registrar, Department of Surgical Oncology, Apollo Speciality Hospitals , Chennai, India . 3. Head and Senior Consultant, Department, of Surgical Oncology, Apollo Speciality Hospitals , Chennai, India . 4. Senior Consultant, Department of Surgical Oncology, Apollo Speciality Hospitals , Chennai, India.
Abstract
BACKGROUND: Peritoneal carcinomatosis (PC) can arise directly from peritoneum (primary) or from regional spread of gastrointestinal and gynecological malignancies. It is often considered a terminal event. CRS/HIPEC procedure provides encouraging outcomes in select sub-set of patients with PC. In this study we present our initial experience of this combined procedure from a tertiary cancer care center in India. MATERIALS AND METHODS: Between January 2014 to January 2015, 13 patients underwent CRS + HIPEC procedure at our center. Preoperative assessment for cytoreduction was done using contrast CT-scan of the abdomen and staging laparoscopy. All procedures were performed by the same surgical team. After cytoreduction, HIPEC was performed by closed method. RESULTS: Median patient age was 52 and median PCI was 13.5 (5-21). Ovarian cancers were commonest origin of PC in our series. All patients had a complete cytoreduction with a median operative time of 8.3 hours. Postoperative ileus was the commonest adverse event. In the immediate postoperative period, major complications were observed in 23% (3/13) of our patients (1. intra-abdominal abscess 2. Septicemia and liver function derangement 3. Bowel obstruction which required a re-operation. Median hospital stay was 12 days (range 9-45 days) and there was no perioperative mortality. CONCLUSION: Our initial results indicate that CRS + HIPEC procedure can be performed with acceptable morbidity and no mortality. Appropriate case selection by a multi-disciplinary team is vital to achieve complete cytoreduction and optimize outcomes.
BACKGROUND:Peritoneal carcinomatosis (PC) can arise directly from peritoneum (primary) or from regional spread of gastrointestinal and gynecological malignancies. It is often considered a terminal event. CRS/HIPEC procedure provides encouraging outcomes in select sub-set of patients with PC. In this study we present our initial experience of this combined procedure from a tertiary cancer care center in India. MATERIALS AND METHODS: Between January 2014 to January 2015, 13 patients underwent CRS + HIPEC procedure at our center. Preoperative assessment for cytoreduction was done using contrast CT-scan of the abdomen and staging laparoscopy. All procedures were performed by the same surgical team. After cytoreduction, HIPEC was performed by closed method. RESULTS: Median patient age was 52 and median PCI was 13.5 (5-21). Ovarian cancers were commonest origin of PC in our series. All patients had a complete cytoreduction with a median operative time of 8.3 hours. Postoperative ileus was the commonest adverse event. In the immediate postoperative period, major complications were observed in 23% (3/13) of our patients (1. intra-abdominal abscess 2. Septicemia and liver function derangement 3. Bowel obstruction which required a re-operation. Median hospital stay was 12 days (range 9-45 days) and there was no perioperative mortality. CONCLUSION: Our initial results indicate that CRS + HIPEC procedure can be performed with acceptable morbidity and no mortality. Appropriate case selection by a multi-disciplinary team is vital to achieve complete cytoreduction and optimize outcomes.
Authors: Jan Franko; Qian Shi; Charles D Goldman; Barbara A Pockaj; Garth D Nelson; Richard M Goldberg; Henry C Pitot; Axel Grothey; Steven R Alberts; Daniel J Sargent Journal: J Clin Oncol Date: 2011-12-12 Impact factor: 44.544
Authors: R C Rietbroek; P J van de Vaart; J Haveman; F A Blommaert; A Geerdink; P J Bakker; C H Veenhof Journal: J Cancer Res Clin Oncol Date: 1997 Impact factor: 4.553
Authors: P J van de Vaart; N van der Vange; F A Zoetmulder; A R van Goethem; O van Tellingen; W W ten Bokkel Huinink; J H Beijnen; H Bartelink; A C Begg Journal: Eur J Cancer Date: 1998-01 Impact factor: 9.162
Authors: N Bakrin; F N Gilly; D Baratti; J M Bereder; F Quenet; G Lorimier; F Mohamed; D Elias; O Glehen Journal: Eur J Surg Oncol Date: 2013-03-16 Impact factor: 4.424
Authors: Thejus T Jayakrishnan; Anthony J Zacharias; Avishkar Sharma; Sam G Pappas; T Clark Gamblin; Kiran K Turaga Journal: World J Surg Oncol Date: 2014-08-21 Impact factor: 2.754
Authors: Cristina Rodríguez Silva; Francisco Javier Moreno Ruiz; Inmaculada Bellido Estévez; Joaquin Carrasco Campos; Alberto Titos García; Manuel Ruiz López; Ivan González Poveda; Jose Antonio Toval Mata; Santiago Mera Velasco; Julio Santoyo Santoyo Journal: World J Surg Oncol Date: 2017-02-21 Impact factor: 2.754